AbbVie subsidiary Allergan Aesthetics has agreed to acquire Soliton, which is commercialising a cellulite treatment based on research at University of Texas.
Soliton, a US-based developer of a medical device to treat cellulite based on research at University of Texas’ MD Anderson Cancer Center, has agreed to an acquisition by Allergan Aesthetics, a subsidiary of pharmaceutical firm AbbVie.
Allergan will pay $22.60 per share in cash for each outstanding share of Soliton, valuing the latter at approximately $550m. The merger has been approved by both boards of directors, but remains subject to customary closing conditions.
The deal follows regulatory clearance…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
